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Immune responses to oral vaccines are impaired in populations living in conditions of poverty in developing countries, and
there is evidence that concurrent geohelminth infections may contribute to this eﬀect. We vaccinated 48 children living in rural
communities in Ecuador with a single oral dose of 100mg of BCG Moreau RDJ and measured the frequencies of tuberculin-
stimulated peripheral blood mononuclear cells expressing IFN-γ before and after vaccination. Vaccinated children had active
ascariasis (n = 20) or had been infected but received short- (n = 13) or long-term (n = 15) repeated treatments with albendazole
prior to vaccination to treat ascariasis. All children had a BCG scar from neonatal vaccination. There was no evidence of a boosting
of postvaccination IFN-γ responses in any of the 3 study groups. Our data provide support for the presence of a barrier to oral
vaccination among children from the rural tropics that appeared to be independent of concurrent ascariasis.
1. Introduction
The use of oral vaccines in children and adults from poor
populations, particularly in the tropics, has been associated
with reduced eﬃcacy and impaired immune responses.
Impaired immune responses have been reported for both
live-attenuated and killed vaccines including Sabin oral polio
vaccine [1], rotavirus [2, 3], cholera [4], Shigella [2, 5], and
a killed Vibrio cholerae O1 plus B subunit vaccine [6]. Such
eﬀects are observed at doses that are highly immunogenic
in subjects from North America or Europe and, in some
circumstances, may be overcome by an increase in the size of
vaccine dose or the number of doses administered [4, 7–9].
Barriers to eﬀective vaccination with oral vaccines in
poor populations living in the tropics include nutritional
deficiencies (e.g., vitamin A and zinc), chronic diarrhoea,
pre-existing mucosal immunity (e.g., intestinal secretory
IgA), the presence of maternal antibodies in breast milk,
environmental enteropathy [3, 4], and coinfections with
enteric bacterial infections, and protozoal (e.g., Giardia
intestinalis) and geohelminth parasites [10]. The geo-
helminth parasites, Ascaris lumbricoides, Trichuris trichiura,
and hookworm have a worldwide distribution and are
strongly associated with poverty. Geohelminths infect an
estimated 2 billion humans [11] and prevalence, in the
case of A. lumbricoides, is highest among preschool and
school age children. Infections are chronic, tend to be
acquired during the second year of life, and may persist
into adulthood through residence in an environment that
is heavily contaminated with human faeces. Geohelminth
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infections have also been associated with impairment of
vaccine immune responses in experimental animal models
[12] and in humans [13–15].
Oral BCG Moreau RDJ is a potent inducer of mucosal
Th1-immune responses [16] and is registered for use in
humans [17]. When given as a single dose to subjects
with a BCG vaccination scar in the UK, oral BCG is able
to boost IFN-γ responses to PPD [16]. Because ascariasis
is associated with strong Th2 immune responses [18]
systemically and at the site of infection in the intestinal
mucosa [19], and Th1 and Th2 responses are considered
to be reciprocally inhibitory [20]. We hypothesized that
concurrent infections with ascariasis would strongly impair
Th1 responses to tuberculin following vaccination with oral
BCG, and that treatment with albendazole before vaccination
would improve this response.
In the present study, we measured IFN-γ response to
tuberculin in vitro before and after vaccination with a single
dose of the live oral vaccine, BCG Moreau RDJ, in children
who were either actively infected with A. lumbricoides
or previously infected but had received either short- or
long-term repeated treatments with the anthelmintic drug,
albendazole, before vaccination.
2. Methods
2.1. Study Design and Subjects. Children attending rural
schools in the districts of Pedro Vicente Maldonado, Puerto
Quito, and San Miguel de Los Bancos in a subtropical
region of Pichincha Province were eligible. Subjects were
selected from a database compiled by the study team for a
cluster-randomized intervention study in which schools were
randomized to receive either 400mg of albendazole every 2
months for a year or no intervention [21]. All children in
this intervention study received a single dose of 400mg of
albendazole at 12 months after the start. Eligible children
were those aged 8–14 years, with a BCG scar on the upper
right arm (parenteral BCG is given at birth in Ecuador),
with no clinical evidence of immunodeficiency or current
illness, and with results available from 3 previous stool
examinations. Girls had a pregnancy test before inclusion.
The study design is shown in Figure 1. Subjects were
recruited into 3 groups. Group 1 (active infection with
A. lumbricoides)—children with a current A. lumbricoides
infection and 3 previous stool samples positive for A. lum-
bricoides. Group 2 (short-term anthelmintic treatment)—
children with a current A. lumbricoides infection and 3
previous stool samples positive for A. lumbricoides. Group
3 (long-term anthelmintic treatment)—children who had
received 7 previous doses of 400mg of albendazole over
the previous 16 months and had a positive stool sample
for A. lumbricoides before the start of treatment but no
positive stool samples for A. lumbricoides infections since
the start of treatment. We compared short-versus long-term
anthelmintic treatments because the immunological eﬀects
underlying putative vaccine hyporesponsiveness associated
with ascariasis may require a significant time period of
being parasite free to be reversed [10, 21, 22]. The study
was conducted between January and May 2005. Informed
written consent was obtained from a parent of each child.
The study protocol was approved by the Ethics Committee
of the Hospital Pedro Vicente Maldonado, Pedro Vicente
Maldonado, Ecuador.
2.2. BCG Vaccination and Albendazole Treatments. Children
in Groups 2 and 3 (short-term and long-term anthelmintic
treatment, resp.) were given two directly observed doses
of 400mg of albendazole spaced 30 days apart with the
last dose given 7 days before vaccination. Group 1 (active
infection with A. lumbricoides) did not receive albendazole
before vaccination. We used the oral BCG, still licensed
for human use in Brazil, prepared from a World Health
Organization, defined seed lot designated Mycobacterium
bovis BCG substrain Moreau Rio de Janeiro by Fundacao
Ataulpho de Paiva, Rio de Janeiro, Brazil. The BCG is
cultured in a proprietary Sauton medium, suspended in
5mL 1.5% sodium glutamate solution in a single 100-mg
dose. The lot used in the present study was shown to
contain 7.5–9.0 × 107 cfu viable bacilli per 100mg dose.
All children were given a single oral dose of 100mg of
BCGMoreau RDJ re-suspended in 50mL of 2% bicarbonate
buﬀer as described previously [16]. A single dose of 400mg
of albendazole was given to all subjects at the end of the
study.
2.3. Blood and Stool Samples. Blood samples (10mL) were
drawn into Vaccutainer tubes (Becton Dickinson) containing
sodium heparin immediately before vaccination and 28 days
after vaccination. Stool samples were collected from children
in all study groups at the beginning of the study and
(before albendazole treatment in Groups 2 and 3 and at the
same time in Group 1) and at 28 days after vaccination.
Stool samples were examined using the modified Kato-Katz
(for quantification of egg counts) and formol-ether acetate
concentration methods [23].
2.4. IFN-γ Enzyme-Linked Immunospot (ELISPOT) Assays.
The frequencies of peripheral blood mononuclear cells
(PBMCs) expressing IFN-γ were measured by ELISPOT as
described previously [16]. Briefly, unfractionated PBMCs
were separated from whole blood and were plated onto
microtiter plates with nitrocellulose membranes (Millipore,
Watford, UK). PBMCs were cultured for 18 hours in
the presence of medium only, tuberculin (PPD; Statens
Serum Institute, Copenhagen, Denmark) at 5 μg/mL and
phytohaemagglutinin (PHA; Sigma-Aldrich, Poole, UK)
at 5 μg/mL in RPMI 1640 medium supplemented with
10% fetal bovine serum, L-glutamine, gentamicin, and 1%
HEPES in a humidified environment with 5% CO2 at
37◦C. Anti-human IFN-γ antibody coating and detection
antibody pairs and detection reagents for ELISPOT were
used according the manufacturers recommendations (BD
Biosciences, Oxford, UK). Spots were counted using an
automated ELISPOT reader (AID Elispot Reader Systems,
Strassberg, Germany). The background activity of IFN-
γ-secreting cells in control wells was constant (data not
shown).
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Figure 1: Study design. All eligible children had documented stool samples with Ascaris lumbricoides a year before the start of the study.
Children were selected into study groups on the basis if they had or had not received 7 repeated doses of 400mg of albendazole every 2
months over the previous 16 months. Children who had not received long-term albendazole and who continued to have ascariasis were
allocated to 2 groups. Group 1: active A. lumbricoides infection; Group 2: short-term anthelmintic treatment. Children in Group 2 were
given 2 single doses of 400mg albendazole separated by 30 days. Children who had received long-term anthelmintic treatment were selected
into Group 3. Children in Group 3 were given 2 single doses of 400mg albendazole separated by 30 days. All children received a single dose
of oral BCG Moreau RDJ. Blood was collected immediately before vaccination and at 28 days after vaccination to measure IFN-γ responses
to PPD.
2.5. Statistical Analysis. Results were expressed as frequencies
of IFN-γ-expressing cells/106 PBMCs or as a percent change
between postvaccination and prevaccination frequencies.
Intergroup diﬀerences were assessed using the Kruskall-
Wallis test and within group diﬀerences using the Wilcoxon
sign-ranked test, the nonparametric equivalent of the paired
t-test. Post-vaccination changes within individual groups
(compared to no change of 100%) were assessed using
the sign rank test. Associations between study variables
and percent change in frequencies of IFN-γ-expressing
PBMCs (loge transformed) were evaluated using multiple
linear regression. Results of linear regression were back-
transformed to provide fold-change in geometric means. All
analyses were done using Stata, version 10 (Statacorp, College
Station, TX, USA).
3. Results
3.1. Study Population. A total of 48 children that fulfilled the
study eligibility criteria were vaccinated. Baseline character-
istics of the 48 individuals are shown in Table 1. Baseline
age and nutritional status did not diﬀer between the study
groups. There were significantly more males in Group 1
compared to Groups 2 and 3 (P = 0.003). Pretreatment
median infection intensities with A. lumbricoides were mod-
erate in Groups 1 and 2. A high proportion of subjects in
Groups 1 and 2 were infected with T. trichiura (80.0% versus
84.6%, resp.) but infection intensities were low. A surprising
finding was that 53.3% of children in Group 3 were infected
with T. trichiura despite having received repeated doses of
albendazole over the previous 12 months. One individual in
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Table 1: Baseline characteristics of study children. Group 1: active infection with A. lumbricoides; Group 2: short-term anthelmintic
treatment; Group 3: long-term anthelmintic treatment. BMI-body mass index. ∗2 doses of 400mg albendazole over 1 month. ‡7 doses
of 400mg albendazole over 12 months. §: results of stool sample collected before short-term treatment.
Variable
Group 1
(N = 20)
Group 2
(N = 13)
Group 3
(N = 15)
Age
Median (range) 10 (8–13) 10 (8–14) 10 (8–13)
Sex
Male/female 14/6 3/10 3/12
BMI
Median (range) 16.3 (13.2–20.9) 16.4 (13.7–19.2) 16.3 (14.3–26.4)
Hemoglobin (g/dL)
Median (range) 12.3 (11.3–14.0) 12.5 (11.3–14.3) 12.5 (11.5–13.3)
Anthelmintic treatment
Short-term treatment∗ No Yes Yes
Long-term treatment‡ No No Yes
Geohelminth infections
Baseline§
A. lumbricoides 100% 100% 6.7%
Intensity, median (range) epg 7,728 (1,633–72,998) 13,135 (2,627–36,920) 0 (0–19,099)
T. trichiura 80.0% 84.6% 53.3%
Intensity, median (range) epg 568 (0–18,744) 213 (0–5,893) 0 (0–1,633)
Hookworm 5.0% 0% 6.7%
Postvaccination
A. lumbricoides 85.0% 0% 0%
Intensity, median (range) epg 11,041 (0–135,965) 0 (0-0) 0 (0-0)
T. trichiura 85.0% 75.0% 21.4%
Intensity, median (range) epg 604 (0–3,976) 142 (0–9,940) 0 (0–710)
Hookworm 5.0% 0% 0%
each of Groups 1 (5.0%) and 3 (6.7%) were infected with
hookworm.
3.2. Adverse Reactions to Oral BCG. Adverse reactions were
monitored weekly for 28 days after vaccination. Only mild
adverse reactions were reported; headache (total of 15
episodes), fever (2), sore throat (1); diarrhea (3); changes
in cervical lymphadenopathy (all 48 subjects had palpable
cervical nodes before vaccination but no changes were noted
over 28 days of observation).
3.3. Frequencies of IFN-γ-Expressing PBMCs. Data from
1 subject were excluded from the analysis because of a
failure to produce detectable IFN-γ-expressing PBMCs to
any of stimuli including mitogen after vaccination. PHA-
induced frequencies of IFN-γ-expressing PBMCs were sim-
ilar between the three groups before and after vaccination.
Pre- and postvaccination frequencies of IFN-γ-expressing
PBMCs following stimulation with PHA were Group 1 (pre-
vaccinationmedian 1805.6×106 PBMCs, IQR 1016.7–2000.0
versus postvaccination median 1180.0, IQR 553.3–2000.0),
Group 2 (prevaccination median 1808.9, IQR 1555.6–2000.0
versus post-vaccinationmedian 1634.4, IQR 1249.2–2000.0).
and Group 3 (prevaccination median 1671.1, IQR 1102.2–
2000.0 versus postvaccination median 1277.8, IQR 1108.2–
1893.3). The frequencies of PPD-induced IFN-γ-expressing
PBMCs did not change significantly within any of the 3 study
groups after vaccination and did not diﬀer between the 3
groups either before or after vaccination (Figure 2). Pre- and
post-vaccination frequencies of IFN-γ-expressing PBMCs
were Group 1 (prevaccination median 95.6 × 106 PBMCs,
IQR 26.3–238.9 versus postvaccination median 122.2, IQR
70.0–206.7), Group 2 (prevaccination median 102.2, IQR
57.8–306.7 versus postvaccination median 195.6, IQR 106.7–
475.6), and Group 3 (prevaccination median 84.4, IQR
55.6–246.7 versus postvaccination median 104.4, IQR 57.8–
208.9). Percent changes in frequencies comparing post-
with prevaccination frequencies were: all subjects (median
104.5%, IQR 60.1–333.3%), Group 1 (median 95.4%, IQR
63.1–350.0%), Group 2 (median 140.4, IQR 67.9–320.1),
and Group 3 (median 92.9%, IQR 50.0–170.9%). There was,
therefore, no evidence for postvaccination boosting of IFN-
γ responses in this study population, although a trend of
postvaccination boosting in Group 2 that received short-
term anthelmintic treatment was seen. To see if individ-
uals with low IFN-γ responses to PPD before vaccination
increased their responses after vaccination, we stratified
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Figure 2: Frequencies of PPD-stimulated PBMCs expressing IFN-γ before and after vaccination with oral BCG Moreau. Frequencies were
measured by ELISPOT. Graphs are (a) frequencies of PBMCs before (pre-) and after (post-)vaccination in active infection (clear), short-
term anthelmintic treatment (grey), and long-term anthelmintic treatment (hatched) study groups; (b) percent changes in frequencies
postvaccination compared to prevaccination. 100% shows no change. Shown are box plots with median (central line), interquartile range
(box margins), 95% confidence intervals (bars), and outlying values (circles).
prevaccination responses into low and high representing
values below and above the 25th centile of values for all
subjects prevaccination (or 44 IFN-γ-expressing cells per
106 PBMCs). The proportions of subjects with low PPD
responses prevaccination were Group 1 (8/20 or 40%),
Group 2 (1/12 or 8%), and Group 3 (3/15 or 20%). Six of
these 12 (50%) “low-responder” individuals responded to
vaccination (5/8 in Group 1; 0/3 in Group 2, and 1/1 in
Group 3) by becoming “high responders” after vaccination.
3.4. Factors Associated with Percent Change in Frequencies of
IFN-γ-Expressing PBMCs. We did an exploratory analysis to
see if any baseline variables were associated with percent
change in frequencies of IFN-γ-expressing PBMCs. Univari-
ate analyses showed significant association with age (Fold-
change 1.59, 95% CI 1.04–2.42, P = 0.03) but not sex (FC
0.69, 95%CI 0.86–1.11), hemoglobin (FC 1.56, 95%CI 0.93–
2,62, P = 0.09), body mass index (FC 1.42, 95% CI 0.74–
2.74, P = 0.29), and presence of prevaccination infections
with T. trichiura (FC 0.85, 95% CI 0.40–1.81, P = 0.68)
and A. lumbricoides (FC 1.15, 95% CI 0.56–2.32, P = 0.70).
After multivariate analyses that controlled for these factors,
the eﬀect of age (FC 1.16, 95% CI 0.90–1.51, P = 0.24) lost
statistical significance.
4. Discussion
Infectious diseases are a major cause of death and mor-
bidity in populations living in developing countries and
vaccination is the most eﬀective public health strategy to
reduce this disease burden. Many of the vaccines in use
or under development for preventing infectious diseases
are or will be delivered via the oral route [3, 4] and
the poor eﬃcacy and immunogenicity of such vaccines in
poor populations represents a major barrier to the success
of public health initiatives aimed at reducing infectious
diseases. Geohelminth infections represent a potentially
important cofactor that may contribute to vaccine hypore-
sponsiveness in underprivileged populations [13–15] and
is easily modifiable given the wide availability of highly
eﬀective and cheap treatments. In the present study, we
investigated the eﬀect of concurrent infections with ascariasis
on the immune response to a single booster dose with oral
BCG. We measured vaccine immune responses using IFN-
γ responses to tuberculin. Our data provide evidence that
a booster dose of oral BCG did not significantly enhance
IFN-γ responses in this population overall (104.5% change
in IFN-γ-expressing cell frequencies) but this eﬀect did not
appear to be associated with ascariasis because neither short
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nor long-term repeated treatments with albendazole had
any significant eﬀect on IFN-γ responses. The failure of
oral BCG to boost IFN-γ responses at a dose that is highly
immunogenic in adult volunteers from the United Kingdom
[16] provides further evidence for an immunological barrier
to mucosal immunization in tropical populations.
Two previous studies have provided evidence that geo-
helminth infections may interfere with immune responses
to vaccines: (1) Ecuadorian children infected with A. lum-
bricoides (infection intensity >10,000 eggs per gramme of
faeces) were randomized to receive either 2 doses of alben-
dazole or placebo separated by 30 days and then vaccinated
with a single dose of 5 × 108 cfus of the live-attenuated oral
cholera vaccine, CVD 103-HgR, a dose shown previously to
be suboptimal in populations of low socioeconomic status
[8]. Vibriocidal antibodies and cellular responses to cholera
B-subunit (CT-B) were measured. The results provided some
evidence that pretreatment of ascariasis before vaccination
improved both vibriocidal antibody levels [13] and Th1
cytokine responses to CT-B [14], but in the case of vibrio-
cidal antibody levels there was a significant interaction with
ABO blood group [13]. (2) Ethiopian adults infected with
geohelminths, and presumed not to have been vaccinated
previously with BCG, were randomized to receive either two
doses of albendazole or placebo separated by 1 month, and
those that were Mantoux-negative post-treatment were vac-
cinated with parenteral BCG. Production of IFN-γ protein
was measured in supernatant fluids from PBMC cultures and
there was evidence for a significant postvaccination increase
in IFN-γ production in the albendazole-treated group while
no change was observed in the placebo group [15]. Similarly,
Heligmosomoides polygyrus a natural and chronic infection of
themouse small intestine, was associated with impaired IFN-
γ production to OVA following vaccination with a novel oral
OVA-expressing Salmonella vaccine [12].
There is evidence, therefore, that intestinal helminth
infections may interfere with immune responses to oral
vaccines. The finding of no eﬀect of concurrent ascariasis
on IFN-γ responses to PPD following vaccination with oral
BCG indicates that infections with A. lumbricoides alone
are unlikely to explain impaired immunity to oral vaccines.
Other factors such as poor nutrition and immune deficiency
associated with concurrent infections (e.g., HIV, tuberculo-
sis, and malaria) may contribute to immune hyporespon-
siveness to an oral vaccine. However, none of the children
in the present study had evidence of significant nutritional
abnormalities: none had hemoglobin levels below 11 g/dL or
BMI values of 2 standard deviations below the mean for age.
Further, neither of these nutritional parameters appeared to
be associated with frequencies of IFN-γ-secreting PBMCs.
Similarly, coinfections with powerful suppressive eﬀects on
the immune response such as HIV, malaria, and tuberculosis
were of very low prevalence in our study population. Other
chronic enteric parasitic infections that could contribute
to hyporesponsiveness to oral vaccines include G. intesti-
nalis and E. histolytica. Although not investigated in the
present study, cysts of G. intestinalis and E. histolytica/dispar
have been detected in 22.2% and 15.6%, respectively, of
children aged 10 years living in the area where the study
was conducted from a previous survey using standard
microscopic detection in feces (Cooper et al., unpublished
data). A significant proportion of children living in the
rural tropics may have environmental enteropathy that has
been associated with a histologic picture of blunted villi,
abnormal crypt to villus ratio, and increased inflammatory
cell infiltrate in the lamina propria [24, 25]. Environmental
enteropathy is considered to be a major determinant of
growth faltering in infants [26] living in unhygienic and
unsanitary environments associated with intense exposure
to enteric pathogens and may be contribute to a blunting
of mucosal immunity [4]. Experimental animal infections
with geohelminths are associated with the development of
a Th2-mediated enteropathy [27], and there is evidence that
geohelminth infections of humans may cause or contribute
to histologic changes in the small intestine typical of
environmental enteropathy [28].
We chose A. lumbricoides as the geohelminth infection
of interest because previous surveys in the same area have
shown that it is the most prevalent geohelminth present in
our study population [21], because it resides in the small
intestine where it may modify the mucosal immune response
[19], which is also the primary site of attachment to and
immune stimulation by oral vaccines, and because of our
previous observations of the eﬀects of concurrent ascariasis
on the immune response to a live oral vaccine [13, 14].
We compared IFN-γ responses to PPD between 3 groups:
children with active infections with A. lumbricoides (Group
1), and children who were infected but had received either
short- (Group 2) or long-term (Group 3) treatments with
albendazole prior to vaccination. The short-term treatment
group was chosen to examine the short-term eﬀects of
Ascaris expulsion on vaccine responses: 2 doses of 400mg of
albendazole were given amonth apart to ensure eﬀective cure
of ascariasis, to allow early recovery of the gastrointestinal
mucosa, and to prevent the establishment of new infections
due tomigrating larvae. A trend of increased IFN-γ-secreting
PBMCs was observed in Group 2 that received short-term
anthelmintic treatment and a larger study might have shown
a significant eﬀect. The long-term treatment group was
chosen to examine the long-term eﬀects of maintaining the
small intestine free of A. lumbricoides infections for a period
of greater than a year. Such treatments should allow any long-
term immunological or pathological eﬀects of ascariasis on
mucosal immune responses to be reversed if reversible. It is
not clear why an eﬀect on IFN-γ responses, if real, should
have been observed for short but not long-term anthelmintic
treatment.
Oral BCGMoreau RDJ was given routinely in Brazil until
the 1970s when intradermal immunization was initiated to
fall in line with the WHO EPI programme [17]. Overall, the
safety data available from wide scale vaccinations in Brazil
and Argentina indicate that oral BCG has an equivalent or
superior safety profile compared to intradermal vaccinations
[29, 30]. The immunological adjuvant eﬀects of oral BCG
and the ability to construct recombinant derivatives engi-
neered to provide simultaneous vaccination to other mucosal
pathogens [31] makes it an attractive vector for novel
mucosal vaccines. Oral BCG Moreau RdJ has an excellent
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safety profile when administered at a dose of 100mg and the
risks are minimal [16, 17]. The only severe adverse event that
has been associated with oral BCG Moreau RdJ in Brazil is
suppurative adenitis, but with an extremely low frequency
comparable to intradermal BCG. Minor adverse events
associated with the vaccine include diarrhoea, vomiting,
headache, sore throat, and cervical lymphadenopathy [16,
17]. Our observations from the present study support the
excellent safety profile of this vaccine in a population of
children living in the rural tropics.
5. Study Limitations
The study was designed as a pilot study to provide data that
could be used to design an adequately powered randomized
intervention study. The sample size was, therefore, small
and we had limited power to detect significant eﬀects. We
measured the vaccine immune response to BCG using IFN-
γ responses to PPD. Although PPD measures antimycobac-
terial immunity in general, an increase following oral BCG
can be assumed to be due to enhanced immune responses to
the vaccine itself and provides a reasonably robust method to
measure postvaccination responses although such responses
do not necessarily reflect enhanced protective immunity
to Mycobacterium tuberculosis. Mucosal immune responses
were measured at 28 days after vaccination at which time
antigen-specific lymphocytes traﬃc between mucosal tissues
in the systemic circulation [32]. The 28-day time point was
based on the findings of a previous study that used the
same vaccine as a booster dose in healthy volunteers in the
UK, in a population that received BCG during childhood
or adolescence and showed maximal IFN-γ responses for
PPD at 1 and 3 months after vaccination [16]: the mean rise
in IFN-γ frequencies at 1 months was ∼3-fold with similar
prevaccination frequencies as observed in the present study
(∼ 100×106 IFN-γ-expressing PBMCs/mL). An explanation
for a failure to observe postvaccination boosting of IFN-γ
responses could relate to the kinetics of traﬃcking of PPD-
responsive lymphocytes in: (a) children with a “damaged”
enteropathic gut; (b) children that received BCG at birth;
(c) circumstances in which exposures to environmental
mycobacteria are likely to be diﬀerent. A possible explanation
for the failure of anthelmintic treatment to boost IFN-γ
responses to PPD was the persistence of T. trichiura infec-
tions in both treatment groups, although postvaccination
frequencies or changes in frequencies did not appear to diﬀer
by prevaccination T. trichiura infection status. Repeated
doses of albendazole, although highly eﬀective against A.
lumbricoides, were of limited eﬃcacy against infections with
T. trichiura in this study. Similar observations have been
made previously for single [33] and multiple doses of
albendazole [21]. Although T. trichiura resides in the large
intestine and, to aﬀect vaccine responses would have tomedi-
ate inhibitory eﬀects at the site of the interaction between
the intestinal mucosa and BCG in the small intestine, there
is evidence that T. trichiura may have regulatory eﬀects at
distal sites [34]. Future studies could examine the potential
eﬀects of T. trichiura infection, specifically, on immune
responses to oral vaccines. Although the dose of oral BCG
used for prophylaxis against tuberculosis has varied in Brazil
[17], a single dose of 100mg has been used for individuals
without a history of contact with tuberculosis for many
years [17]. For experimental studies in humans, single or
multiple 100mg doses of oral BCG have been administered
either with 2% sodium bicarbonate (to neutralize gastric
acidity) immediately before [30] or with vaccine [16] or
without sodium bicarbonate buﬀer [35]. Although oral BCG
has proved to be immunogenic using both approaches [16,
30, 35], a possible explanation for our negative findings are
eﬀects of gastric acidity on vaccine immunogenicity.
6. Conclusion
Our data show that children living in the rural tropics
failed to respond to a single booster dose of oral BCG
Moreau RDJ with an increased IFN-γ response to PPD. This
apparent barrier to mucosal immunization appeared to be
independent of ascariasis and was not significantly aﬀected
by treatment of these infections before vaccination. Our data
provide further evidence for a barrier to oral vaccination in
populations living in circumstances of poverty in developing
countries that poses a major hurdle to the strategy of oral
immunization in such populations unless steps are taken to
improve mucosal health. One such measure would be to give
anthelmintic treatment before vaccination, but as the present
study shows, this intervention alone may provide limited
benefits.
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